by Team Small News | Oct 24, 2025 | Pfizer, Pharma
Pfizer Canada has announced that its vaccine, ABRYSVO, for the prevention of Respiratory Syncytial Virus (RSV), will be publicly funded in multiple provinces and territories across Canada for the 2025-2026 season. This decision reflects the growing recognition of the... by Team Small News | Oct 22, 2025 | Pfizer, Pharma
Pfizer’s Accord for a Healthier World program is a comprehensive initiative aimed at addressing healthcare disparities by providing the company’s full portfolio of medicines and vaccines on a not-for-profit basis to 45 lower-income countries. However, many... by Team Small News | Oct 21, 2025 | Pfizer, Pharma
The allergy treatment market is expected to experience significant growth in the coming years, driven by increasing awareness and prevalence of allergies worldwide. According to a recent report, the market is anticipated to expand due to the rising demand for... by Team Small News | Oct 10, 2025 | Pfizer, Pharma
The medical community worldwide is reeling from a recent US court decision that has forced the Food and Drug Administration (FDA) and Pfizer to release confidential documents related to COVID-19 vaccine side effects. Initially, these documents were set to be made... by Team Small News | Oct 9, 2025 | Pfizer, Pharma
The pharmaceutical industry is facing potential challenges despite the recent deal between Pfizer and the Trump administration. In November 2020, the US government announced a $1.95 billion deal with Pfizer to provide 100 million doses of its COVID-19 vaccine.... by Team Small News | Oct 8, 2025 | Pfizer, Pharma
The National Institute for Health and Care Excellence (NICE) has recently recommended Pfizer’s Lorviqua (lorlatinib) as a first-line treatment for certain types of lung cancer in England. This decision follows the publication of NICE’s final guidance on...